REMARKS/ARGUMENTS

The Pending Claims

Claims 15-19 are pending and are directed to a method of increasing the oral bioavailability of glycopyrrolate to a patient. The Office Action indicated that the subject matter of claims 15-19 was free of the prior art and, thus, allowed.

Amendments to the Claims

Claims 1-14 have been canceled to expedite prosecution. Accordingly, the rejection is now moot and should be withdrawn. The cancellation of claims 1-14 is not a concession regarding the merits of the rejection set forth in the Office Action. Moreover, Applicants do not abandon the subject matter of these claims. Applicants reserve the right to pursue any canceled subject matter in a continuation, continuation-in-part, divisional application, or other application.

Claims 15-27 were previously canceled in response to a restriction requirement by the Office. Claims 28-29 (that depend on claim 27) were inadvertently omitted from the restriction requirement set forth in the Office Action dated August 1, 2005 as well as Applicants' reply dated August 30, 2005. Accordingly, the claims amendments in this response include the cancellation of claims 28-29.

Copending and Related Applications

The Office has requested a list of all co-pending and related applications. Applicants have provided a copy of WO 01/08681 in the IDS submitted on March 25, 2004. There are no related applications that are currently pending or have been previously abandoned.

Conclusion

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

Steven H. Sklar, Reg. No. 42,154
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: January 17, 2006

Amendment or ROA - Regular (Revised 2005 11 04)